Results 21 to 30 of about 463,492 (156)

Multicentre randomised controlled trial of balloon pulmonary angioplasty and riociguat in patients with chronic thromboembolic pulmonary hypertension: protocol for the MR BPA study

BMJ Open, 2020
IntroductionManagement of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) remains a clinical challenge. Currently, medical treatment involving pulmonary vasodilators (such as soluble guanylate-cyclase stimulators) is recommended ...
Hiromi Matsubara, Kohtaro Abe, Toshiro Shinke   +2 more
doaj   +1 more source

Guanylate cyclase activators and stimulators. Potential cardiovascular therapeutics, with special focus on the right ventricle [PDF]

, 2022
Background - Soluble guanylate cyclase, sGC, is a major contributor to the signal transduction in the cardiovascular system, and dysfunction in the NO-sGC-cGMP signaling plays an important role in cardiovascular disease.
Næsheim, Torvind
core   +1 more source

Modern view on the place of riociguat in the treatment of pulmonary hypertension [PDF]

Терапевтический архив, 2018
Current research is aimed at studying the fundamental therapeutic targets and discovering new drugs acting on previously set targets. Until recently, the only therapeutic strategy to influence the molecular pathway of nitric oxide (NO) – soluble ...
Z.S. Valieva, I.N. Taran, T.V. Martynyuk, I.Ye. Chazova   +3 more
doaj   +2 more sources

Responsiveness of rat aorta and pulmonary artery to cGMP generators in the presence of thiol or heme oxidant

Journal of Pharmacological Sciences, 2019
This study investigated the effects of thiol and heme oxidants on responsiveness to cGMP generators in isolated rat aorta and pulmonary artery using an organ chamber.
Masashi Tawa, Yuka Yamashita, Takayoshi Masuoka, Katsuya Nakano, Junko Yoshida, Matomo Nishio, Takaharu Ishibashi   +6 more
doaj   +1 more source

Soluble Guanylate Cyclase Stimulators for Chronic Thromboembolic Pulmonary Hypertension Patients Treatment: New Data

Рациональная фармакотерапия в кардиологии, 2020
This narrative review describes and appraises some relatively new studies investigating the efficacy and safety profile of soluble guanylate cyclase stimulator riociguat in patients suffering from pulmonary arterial hypertension (PAH) and chronic ...
M. A. Simakova, O. M. Moiseeva
doaj   +1 more source

Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis [PDF]

, 2016
Background: Fibrosis and vascular disease are cardinal features of systemic sclerosis (SSc). Stimulators of soluble guanylate cyclase (sGC) are vasoactive drugs that are currently being evaluated in phase III clinical trials for pulmonary arterial ...
Akhmetshina, Alfiya, Distler, Jörg H. W., Beyer, Christian, Hirth-Dietrich, Claudia, Reich, Nicole, Schindler, Sonia C., Dees, Clara, Schett, Georg, Distler, Oliver, Tomcik, Michal, Sandner, Peter, von Degenfeld, Georges   +11 more
core   +2 more sources

Drug repurposing—a promising approach for patients with angina but non-obstructive coronary artery disease (ANOCA)

Frontiers in Cardiovascular Medicine, 2023
In today’s era of individualized precision medicine drug repurposing represents a promising approach to offer patients fast access to novel treatments.
Johanna McChord, Valeria Martínez Pereyra, Sarah Froebel, Raffi Bekeredjian, Matthias Schwab, Matthias Schwab, Peter Ong   +6 more
doaj   +1 more source

Pharmacological effects of a new soluble guanylate cyclase stimulator in experimental pulmonary arterial hypertension

Бюллетень сибирской медицины, 2023
Aim. To assess the effect of an indolinone derivative (2-[2-[(5RS)-5-(hydroxymethyl)-3-methyl-1,3-oxazolidine-2yliden]-2-cyanoethylidene]-1H-indole-3(2H)-one (codename – GRS) on right ventricular contractility, endothelial vasodilator function, and ...
V. V. Bykov, A. V. Bykova, S. A. Stankevich, O. I. Aliev, A. V. Sidekhmenova, O. I. Dunaeva, V. A. Khazanov, A. I. Vengerovskii, V. V. Udut   +8 more
doaj   +1 more source

Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations

Therapeutics and Clinical Risk Management, 2022
Hayah Kassis-George,1 Nathan J Verlinden,1 Sheng Fu,2 Manreet Kanwar1 1Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, USA; 2Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, SC ...
Kassis-George H, Verlinden NJ, Fu S, Kanwar M   +3 more
doaj  

Recent Advances in the Treatment of Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases

Pharmaceuticals, 2023
Pulmonary hypertension (PH) is a severe vascular complication of connective tissue diseases (CTD). Patients with CTD may develop PH belonging to diverse groups: (1) pulmonary arterial hypertension (PAH), (2) PH due to left heart disease, (3) secondary PH
Anna Smukowska-Gorynia, Weronika Gościniak, Patrycja Woźniak, Sylwia Iwańczyk, Karolina Jaxa-Kwiatkowska, Sylwia Sławek-Szmyt, Magdalena Janus, Jerzy Paluszkiewicz, Tatiana Mularek-Kubzdela   +8 more
doaj   +1 more source